Open tender · Germany · Contract notice
Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Certolizumab pegol, ATC L04AB05 für die Zeit 01.08.2025 - 31.07.2027
DAK-Gesundheit in Germany is inviting bids for “Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Certolizumab pegol, ATC L04AB05 für die Zeit 01.08.2025…”. Bids close on 5 June 2027.
The work
Non-exclusive discount agreement for Certolizumab pegol for DAK-Gesundheit.
- Agreement ends automatically with exclusive contract
Key facts
- Contract period
- 01.08.2025 - 31.07.2027
- Evaluation
- Selection criteria referenced in application letter
What it takes to qualify
Worth a closer look
- § 130a Abs. 8 SGB V enables health insurance funds and pharmaceutical companies to conclude framework discount agreements for medicinal products to be charged to the statutory health insurance funds.
- The DAK-Gesundheit assumes that this procedure does not fall within the scope of cartel procurement law due to a lack of selection decision and thus the non-discriminatory access of all pharmaceutical companies.
- The contract documents are available for download via the online portal www.dtvp.de/center under the link mentioned under 5.1.11.
- The offer is to be submitted in text form as an electronic offer via email to openhouse@dak.de.
- The publication is done using the form for open procedures. As already clearly stated, this is such a non-exclusive procedure - the notice had to be used for technical reasons as there is no suitable form for approval procedures.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Angebotsschreibensubmitted via email to openhouse@dak.de
- Vertrag mit Namen oder Firmenstempelacknowledging contractual terms and discounts
- Anlage 1 zum Vertragto be filled out and submitted via email
- Anlage 2 zum VertragExcel file to be sent via email